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Surgery in Pediatric Crohn’s Disease: Indications, Timing 
and Post-Operative Management
Seung Kim
Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
Pediatric onset Crohn’s disease (CD) tends to have complicated behavior (stricture or penetration) than elderly onset 
CD at diagnosis. Considering the longer duration of the disease in pediatric patients, the accumulative chance of 
surgical treatment is higher than in adult onset CD patients. Possible operative indications include perianal CD, in-
testinal stricture or obstruction, abdominal abscess or fistula, intestinal hemorrhage, neoplastic changes and medi-
cally untreatable inflammation. Growth retardation is an operative indication only for pediatric patients. Surgery can 
affect a patient’s clinical course, especially for pediatric CD patient who are growing physically and mentally, so the 
decision should be made by careful consideration of several factors. The complex and diverse clinical conditions 
hinder development of a systemized treatment algorithm. Therefore, timing of surgery in pediatric CD patients should 
be determined with individualized approach by an experienced and well organized multidisciplinary inflammatory 
bowel disease team. Best long-term outcomes will require proactive post-operative monitoring and therapeutic mod-
ifications according to the conditions.
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INTRODUCTION
Crohn’s disease (CD) is a chronic relapsing in-
flammatory disease that mainly affects the gastro-
intestinal tract. It is thought to develop as a result of 
the abnormal immune reaction triggered by several 
environmental factors in genetically susceptible 
individuals. The incidence of CD is rapidly increasing 
worldwide, and up to 25% of patients are diagnosed 
during childhood or adolescence [1]. Pediatric onset 
CD tends to have a more complicated behavior (stric-
ture or penetration) than elderly onset CD at diag-
nosis [2]. Furthermore, considering the longer dura-
tion of disease in pediatric patients, the accumu-
lative chance of surgical treatment is higher than 
adult onset CD patient [3]. 
The paradigm of medical treatment for pediatric 
CD has changed with the emergence of effective bio-
logic agents including infliximab and adalimumab 
[4]. Decreased surgery rate has been associated with 
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Table 1. Operative Indications in Crohn’s Disease
Complex perianal fistula or abscess
Intestinal stricture or obstruction
Intra-abdominal abscess





Fulminant disease which is not responds to the medical treatment
successful use of immunomodulator or biologic 
agent [5,6]. However, other recent reports suggested 
that the rates of cumulative surgical treatment are 
not decreased significantly [7,8]. The dichotomy 
might be due to the extension of surgery indications 
or decreased physician reluctance to perform surgery 
in CD. Surgery is still needed for CD patients even in 
era of anti-tumor necrosis factor (TNF) use. However, 
surgery remains a critical decision for a patient; sur-
gery can greatly affect one’s clinical course, espe-
cially pediatric CD patients who are growing physi-
cally and mentally. The decision regarding surgery 
needs to involve careful consideration of several 
factors. In this article, we review operative indications 
and the proper timing of CD surgery and post-oper-
ative management. 
ROLES OF SURGERY IN CD 
CD is not a completely curable disease. So, surgery 
is not meant to be curative, but rather to relieve 
symptoms or complications of CD. Surgery can pro-
vide immediate relief of mechanical stress or focal 
inflammation, producing immediate improvements 
in symptoms and quality of life. Generally suggested 
surgery indications are listed in Table 1. 
Physicians can rely on a medical treatment for too 
long. As well, patients can refuse surgery until their 
condition demands surgical intervention. Both can 
delay surgery and lead to increased morbidity [9]. 
Many patients and physicians can have an ex-
aggerated fear of CD surgery, which can worsen the 
prognosis. This reluctance is regrettable. In one adult 
study, among 70 patients who have received ileoco-
lonic resection and anastomosis for CD, no one re-
gretted the decision for surgery, with the general 
view being that surgery should have been done 12 
months earlier (95% confidence interval, 7 to 18 
months) [10]. 
But, the incidence of operation-related complica-
tions is not negligible. In one adult study, the rate of 
operation site infection was higher in inflammatory 
bowel disease (IBD) patients (18%) than in colon 
cancer patients (12%) or diverticulitis (12.8%) pa-
tients [11]. Similarly, the rate of reoperation within 
30 days was also higher in IBD patients (7.3%) than 
in colon cancer patients (4.9%) or diverticulitis 
(4.4%) patients. Even if the clinical symptoms are re-
lieved after surgical resection of intestine, bowel in-
flammation remains and clinical situations requir-
ing further operation frequently occur. Other au-
thors reported that cumulative clinical recurrence 
rates in pediatric patients at 1 year, 5 years and 10 
years were 50%, 73% and 77%, respectively [12]. 
Consequences of bowel damage during surgery can 
accumulate with time and can result in digestive 
dysfunction in the long run [13]. For these reasons, 
decision making about surgery should be done pru-
dently by multidisciplinary team approach consider-
ing the risks and benefits.
PERIANAL CD
Several kinds of perianal disease can occur in CD. 
Severity ranges from simple skin tags or anal fissures 
to complicated perianal fistulas or abscesses. Perianal 
CD is common in pediatric patients with an in-
cidence ranging from 13.6% to 62% [14]. Prompt 
drainage of focal septic focus and conservative sur-
gery with appropriate combined medical treatment 
are three general principles about perianal CD [15]. 
However, as the conditions are complex and have 
great diversity, it is difficult to suggest a systemized 
treatment algorithm, and individualized approaches 
according to the patient conditions are required [16]. 
Perianal skin tags generally do not regress com-
pletely, but usually do not require surgical treatment 
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as the lesions remain benign and stable. Anal fis-
sures sometimes recur but usually can be healed 
with medical treatment [17]. 
Diverse types of perianal abscesses can occur in 
CD. Their exact mechanisms of pathogenesis are not 
fully understood. These lesions are frequently re-
lated with bowel inflammation and are not treatable 
using one treatment modality. Surgical intervention 
and medical treatments, such as antibiotics, im-
munomudulators, or biologic agents, should be com-
bined in most cases. Antibiotics like metronidazole 
and ciprofloxacin are used as first-line treatment for 
perianal abscess. The abscess cavity should always be 
drained if it is not resolved with medical treatments 
[18]. Simple skin incision or silastic drain can be 
placed according to the abscess location and size. 
Internal drainage from the anal canal or rectum 
without external skin incision is not preferred be-
cause the abscess can recur in a short time [17].
Simple perianal fistula confined to the anal canal 
or located superficially heals spontaneously without 
surgical management in 50% of cases [19]. In con-
trast, complex fistula or fistula to adjacent organ re-
quire surgical treatment because those lesions do not 
heal completely with a medical approach [17]. Because 
treatment strategies differ according to the type of 
perianal disease, thorough assessment about the le-
sions is necessary before treatment. Rectal examina-
tion, endoscopic ultrasound, magnetic resonance 
imaging (MRI), and examination under anesthesia 
are usually used. Due to its high sensitivity and spe-
cificity and lack of radiation exposure, MRI is consid-
ered to be the radiologic study of choice in most cases 
[17]. Seton procedures, which drain inflammatory 
exudates from the fistula track, are frequently used 
and are useful for complex perianal fistula. Combined 
medical treatment, such as with anti-TNF antibody, 
can control the bowel inflammation and result in de-
layed healing of perianal fistula [20]. In patients 
with severe, complicated perianal disease, fecal di-
version with ileostomy or colostomy can be an option. 
After controlling perianal inflammation, ostomy can 
be repaired. Although data from pediatric studies are 
insufficient, adipose-derived mesenchymal stem cell 
treatment for complex perianal fistulas in CD showed 
efficacy [21].
STRICTURE
Stricturing lesions can develop from anywhere in 
the gastrointestinal tract in CD. These lesions can 
cause symptoms that require some kind of inter-
vention. Intestinal stricture due to inflammation 
should first be managed with medication. Sympto-
matic fibrostenotic lesions require physical dilation. 
Computed tomography enterography and MR enter-
ography have high sensitivity and specificity in dis-
criminating inflammatory and fibrostenotic lesion, 
sometimes it is difficult to figure out the character of 
the lesions and in many cases both characters are 
combined. Endoscopically accessible short segment 
(＜5 cm) stenosis is a good candidate for endoscopic 
dilatation [22]. Although the evidence for endo-
scopic dilatation in CD is from adult studies, it can be 
effective for pediatric patients as well [23]. However, 
stricture connected to the fistula or abscess is a con-
traindication for endoscopic dilatation [24]. Surgery 
is indicated for patients with symptomatic bowel 
strictures that do not respond to medical therapy or 
lesions for which endoscopic approaches are impos-
sible or contraindicated. Bowel resection or surgical 
stricureplasty can be performed for those lesions. As 
strictureplasty can reserve bowel length, it is pre-
ferred over bowel resection for nonphlegmonous 
strictures. 
OBSTRUCTION
Intestinal obstructions are a common indication 
for surgery in CD; approximately 25% of all CD pa-
tients will undergo surgery for this reason [25]. 
There are several mechanisms of intestinal ob-
struction for CD patients. Chronic gradual fibrosis 
can cause obstructive symptoms and acute in-
flammation can also cause intestinal obstruction due 
to edematous intestinal mucosa. In many cases both 
acute and chronic lesions exist at the same time and 
cause obstruction simultaneously. In patients who 
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have previously had surgery, physicians should take 
into account intestinal adhesion induced obstruction. 
Fiber rich food can become stuck in the stenotic in-
testine and occasionally seed of the fruit or capsule 
endoscopy can also induce acute intestinal obstruction. 
Most cases of obstruction response to conservative 
management, such as nasogastric tube decompression, 
with nil per os and intravenous hydration. If CD 
flares and the obstruction is due to inflammation, an 
anti-inflammatory treatment like corticosteroid can 
be helpful. Surgery is indicated in a medically un-
responsive patient or those with frequently repeated 
obstruction [16].
ABDOMINAL ABSCESSES 
Besides perianal lesions, intra-abdominal ab-
scesses are distinguishing characteristics of CD. These 
abscesses typically originate from intestinal perfo-
rations or penetrating deep ulcers. Abdominal ab-
scesses are mainly located in the ileocecal area and 
are commonly associated with intestinal fistulae 
[16]. According to the proposed algorithm for spon-
taneous intra-abdominal abscess in in pediatric CD 
patients, broad spectrum antibiotics such as piper-
acillin-tazobactam, ticarcillin-clavulnate, meropenem 
or advanced-generation cephalosporin with metro-
nidazole combination should be an initial treatment 
in the case of small sized (≤2 cm) abscess [26]. 
Radiology guided percutaneous drainage is indicated 
for larger abscesses unable to be treated with anti-
biotics alone. The success rate of percutaneous drain-
age exceeds 90% and about half of the patients treat-
ed this way can avoid short-term surgery [27]. How-
ever, percutaneous drainage is not always feasible 
and is often unsuccessful, especially in the case of 
multiloculated or multifocal abscess [22]. In the case 
of absence of clinical improvement within 3 to 5 
days, in spite of antimicrobial treatment with percu-
taneous drainage, follow up image study is required 
and surgical drainage should be considered if the ab-
scess persists [26]. To avoid unnecessarily extensive 
bowel resections or post-operative recurrence, pru-
dent preoperative evaluations and combined medi-
cal treatments are necessary. Ideally, to avoid oper-
ation related complications, corticosteroid should be 
reduced to ＜20 mg/d before surgery if the patient 
was on steroid treatment [21].
ABDOMINAL FISTULA
As CD involves intestine transmurally, fistulae can 
arise from the intestine. Fistulas can develop be-
tween regions of the intestine and also can occur be-
tween intestine and adjacent organ such as skin, 
urologic organ or gynecologic organ. Although in-
tra-abdominal fistulae can arise from anywhere in 
the bowel, most common location is the ileocecal 
area, frequently combined with abscesses [16]. If the 
enteroenteric fistulas have no clinical symptoms, 
they may not be required surgical treatment. However 
if they are symptomatic, surgery is required. Inflamed 
bowel should be resected but noninflamed bowel or 
a secondarily affected adjacent organ, such as blad-
der or vagina, also can be managed with primary clo-
sure [22]. The conditions are usually not urgent, so 
preoperative nutritional supplement and inflammation 
controls should precede surgical repair for better 
prognosis. A significant percentage of fistulas occur 
combined with intraabdominal abscesses; the ab-
scesses should be drained before the surgery if fea-
sible [22]. 
HEMORRHAGE
Only 0.9-6% of CD is complicated with acute severe 
lower gastrointestinal bleeding [28]. Although rare, 
management can be challenging. The bleeding focus 
can be multiple, sometimes difficult to find, and of-
ten not possible to control or approach with 
endoscopy. Medical treatment includes anti-TNF 
therapy, which is regarded as the most effective med-
ical treatment; angiographic interventions can be 
tried as well as a therapeutic approach, but those are 
not always successful and occasionally require surgi-
cal resection of affected lesion [29]. For patients with 
massive bleeding who are not stabilized despite mul-
tiple (>4 units) transfusions of packed red blood cells 
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within 24 hours, those who fail medical manage-
ment, or with recurrent massive hemorrhage, sur-
gery is recommended [30].
GROWTH RETARDATION
Pediatric IBD has distinct features compared to 
adult IBD. Therefore, the therapeutic approach can 
differ, and consideration to growth is one of the most 
important issues for treating children with IBD. 
Severe growth retardation is thought to be a pre-
dictive factor of poor clinical outcome. Insufficient 
attention to linear growth and bone health may re-
sult in impaired final adult height and increased risk 
for fractures [31,32]. About 20% of CD children con-
tinue to have abnormal growth despite CD treatment 
[33]. If growth continues to be impeded despite 
medical treatments like exclusive enteral nutrition 
(EEN), immunomodulator therapy, and use of bio-
logics, intestinal resection should be considered. 
Timely surgery can improve growth in patients who 
are unresponsive to medical treatment [15,34]. 
However, resection surgery should be done for pa-
tients who have definite localized lesion; surgery 
needs to be performed before the adolescent growth 
spurt for the effective catch-up of growth [32].
NEOPLASTIC CHANGES
The risk of colon cancer is increased in those with 
CD compared to the normal population. Although 
uncommon, neoplastic changes can develop in ado-
lescents or young adults. While debatable, long-term 
duration, extensive colitis, chronic active inflam-
mation, and presence of primary sclerosing chol-
angitis may be influential factors for the develop-
ment of colorectal malignancies [22,35]. Guidelines 
in the United States, Britain, and European Crohn’s 
and Colitis Organisation (ECCO) recommend sur-
veillance colonoscopy every 1-2 years after 8-10 years 
duration of disease. For high-risk patients, earlier 
and more frequent surveillance should be considered 
[22,35,36]. Identification of carcinoma or non-
adenoma-like dysplasia associated lesion or mass, 
high-grade dysplasia, or multifocal low grade dys-
plasia from the colon or rectum should prompt con-
sideration of total proctocolectomy. Sporadic ad-
enoma can be managed safely with polypectomy in 
patients without CD [22].
FAILED MEDICAL TREATMENT
Although many medical options are effective for 
treating CD, none are perfect. EEN is relatively safe 
but is difficult to continue for life. Corticosteroids are 
generally effective, but treatment duration needs to 
be limited due to side effects. Anti-TNF agents are 
one of the most potent medicines for CD, but not all 
patients respond. Even the combination of infliximab 
and azathioprine achieved only 56.8% corticoste-
roid-free clinical remission at 26 weeks for adult pa-
tients [37]. Similarly in moderate to severe pediatric 
CD patients, adalimumab could have achieved clin-
ical remission in 33.5% of patients at week 26 [38]. 
Patients with an insufficient response to the medical 
treatment, patients who develop CD complications 
even during medical treatment, patients with severe 
drug-induced adverse events, and poorly compliant 
patients should be considered for surgery as an 
option. When the disease is localized in a short seg-
ment of the gut, the patient is a good candidate for 
surgery. Acute severe colitis or toxic megacolon in 
CD is also an indication for surgery if response to the 
medical treatment is poor [16,22].
POST-OPERATIVE MANAGEMENT OF 
CD
Surgery is not the final solution in CD. An appreci-
able number of patients experience recurrence de-
spite surgery. Danish data of 115 pediatric CD pa-
tients who had surgery chronicled that 50% and 73% 
showed clinical recurrence at 1 year and 5 years, re-
spectively [12]. If endoscopic recurrence is included, 
the rate of postoperative recurrence becomes much 
higher [39]. Endoscopic recurrences are thought to 
precede clinical recurrence and postoperative endo-
scopic surveillances are used to predict and prevent 
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clinical recurrence. The Rutgeerts endoscopic re-
currence scoring system is the most frequently used 
system [40]. In this system, i0 indicates no lesions; i1 
indicates ＜5 aphthous lesions; i2 ＞5 aphthous le-
sions with normal mucosa between the lesions, skip-
ped areas of larger lesions, or lesions confined to the 
ileocolonic anastomosis site; i3 indicates diffuse 
aphthous ileitis with diffusely inflamed mucosa; and 
i4 indicates diffuse inflammation with larger ulcers, 
nodules and/or narrowing. Most (90%) of patients 
scoring i4 score will experience recurrence within 3 
years [41]. Active smoking is the most well-estab-
lished risk factor of postoperative recurrence. Pene-
trating disease, perianal disease, prior intestinal re-
section, and extensive small bowel resection (＞50 
cm) are also risk factors of recurrence [39]. Monitoring 
for disease recurrence and proper actions are re-
quired to maintain remission and better prognosis. 
The ECCO guideline [32] recommends continued 
maintenance treatment in children and adolescents 
after surgically induced remission, with thiopurine 
as the treatment of choice in patients with extended 
disease and those at risk for relapse. Like other treat-
ment strategies for adult patients, ileocolonoscopy 
should be considered 6-9 months after surgery to op-
timize treatment for pediatric patients [42,43]. If the 
Rutgeerts score shows i2 or higher, step-up treat-
ment should be considered [43]. 
CONCLUSION
Medical treatments are evolving and several new 
medications are under development or undergoing 
clinical trial evaluation [44]. Treatment targets have 
changed from clinical remission to mucosal healing 
or deep remission. Patient-reported outcome has be-
come a treatment target as well [45]. In the same 
manner, newer surgical techniques have reduced in-
vasiveness or complications [46]. During the disease 
course, surgery can be a turning point and should be 
regarded as a possible treatment option. It should 
not be regarded as an option to avoid at all costs [16]. 
Although timely surgery is the core in treating CD, it 
is extremely difficult to establish an operation guide-
line in CD, especially in children, due to the great di-
versity between patients and due to the lack of sup-
porting evidence [47]. Gastroenterologists and sur-
geons can have different points of view of the best 
course and it is essential to discuss about the in-
dividual patient before making a decision. Patients 
and their parents should be also involved in for-
mulating a treatment plan. Radiologists and other 
specialists should be part of the multidisciplinary 
IBD team. In conclusion, surgery in pediatric CD pa-
tients requires an individualized approach by an ex-
perienced and well-organized multidisciplinary IBD 
team. For the best long-term outcome, proactive 
post-operative monitoring and therapeutic mod-
ifications according to the conditions are essential.
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